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ORIGINAL ARTICLE
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Abstract
Introduction. A retrospective analysis of the relation between the presence of casting-type calcifications on the mammogram
and the prognosis of breast cancer was performed. Materials and methods. The mammographic tumor features and other
characteristics (invasive tumor size, histological tumor type, grade, nodal, hormone receptor and HER2 status, presence of
lymphovascular invasion) of 55 high-risk breast cancers were studied. Results. After a median follow-up time of 29.1 months,
the median relapse-free survival and overall survival times among breast cancer patients with tumors associated with casting
calcifications were 26.6 and 29.6 months, respectively. The corresponding parameters among patients with tumors not
accompanied by casting calcifications were 54.4 and 58.5 months, respectively. Significant associations were found
between the presence of casting calcifications and the risks of relapse (HR3.048, 95% CI: 1.1168.323, p0.030) or
death (HR3.504, 95% CI: 1.07411.427, p0.038). Positive associations were found between casting calcifications and
ER/PR negativity (p0.015 and p0.003, respectively) and HER2 overexpression (p0.019). Discussion. Our findings
support the theory that breast tumors associated with casting-type calcifications at mammography comprise a disease entity
which exhibits significantly more aggressive behavior and a poorer outcome than do cancers with other mammographic
tumor features.
Breast cancer is a heterogeneous disease as regards
its gene-expression profile [1,2], its pathological and
its mammographic appearance, its biological beha-
vior [37] and the response to oncological treatment
[1,8]. The major progress achieved in the past
decade in the adjuvant treatment of early breast
cancer has contributed to an improvement in breast
cancer-related survival [9]. Improved characteriza-
tion of the different cancers may promote a better
estimation of the outcome of the disease and the
potential benefit provided by the various forms of
adjuvant therapy [1,8]. The prognostic indicators
reflect the stage of the cancer reached during the
progression process and the degree of its aggressive-
ness. The tumor size and nodal status reflecting the
stage of the cancer are classical prognostic factors.
The histopathological type, the grade, the presence
or absence of lymphovascular invasion (LVI), the
expression of the hormone receptors and HER2
rather relate to the biological behavior of the cancer
[4,10]. Nonetheless, more specific indicators for the
better identification of high-risk cases are needed.
The mammographic appearance has recently been
suggested as an independent prognostic factor for
mammography screening-detected breast cancers
[47,11]. Among cancers measuring B15 mm de-
tected by mammography screening, the presence of
casting-type calcifications has been demonstrated to
be a prognostic factor which carries a significantly
(9-fold) higher risk of death as compared with
cancers not associated with this mammographic
abnormality [4]. We set out to study whether this
mammographic feature might be indicative of a
different prognosis in more advanced operable breast
cancer cases. Accordingly, we performed a retro-
spective analysis of the mammographic appearance
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of 55 high-risk breast cancers of patients receiving
uniform oncological treatment. Additionally, we
studied the relation between the presence of cast-
ing-type calcifications and the other characteristics
of the tumors.
Material and methods
The tumors and clinical outcomes of 55 consecutive
high-risk breast cancer patients enrolled in an
adjuvant chemotherapy clinical study after surgery
[12] were studied. Eligible patients had operable
breast cancer with either ]4 lymph node metas-
tases, or apT1 grade-III, ER and PR-negative
tumor with lymph node metastasis, or a grade-III,
ER and PR-negative tumor of any size with lymph
node metastasis and vessel invasion, or a T3 cm,
grade-III, ER and PR-negative tumor. The primary
tumor had to have been resected with a clear margin
of at least 5 mm, but of at least 10 mm provided an
extensive ductal component was present. The pre-
sence of distant metastases had to be excluded by
means of physical examination, chest x-ray, abdom-
inal ultrasound and bone scan. The study had been
approved by the Institutional Review Board of the
University of Szeged, and all enrolled patients gave
written informed consent before being registered as
participating in the study. Forty-seven of the 55
patients enrolled completed 24-week adjuvant dose-
dense sequential doxorubicin-paclitaxel-cyclopho-
sphamide chemotherapy, while in eight cases the
chemotherapy was terminated earlier. After the
chemotherapy, all of the patients underwent post-
operative locoregional radiotherapy unless having
had a relapse earlier, and those with hormone
receptor-positive tumors received tamoxifen [12].
The original mammograms taken before surgery
were retrospectively reviewed. All mammograms
were classified by a single radiologist (KO) blinded
to the pathological and clinical data. The lesions
were categorized by their radiomorphological ap-
pearance into two groups: the lesions with casting
calcifications (BI-RADS: fine linear branching calci-
fications), including any associated abnormality, and
tumors in which casting-type calcifications were
absent [3,4].
After a median follow-up time of 29.1 months, the
relapse-free survival (RFS) and overall survival (OS)
were studied in relation to the mammographic
features, the age of the patient and the characteristics
of the tumor (the tumor size, the number of involved
lymph nodes, the histology, the grade, the hormone
receptor status, the HER2 status, and the presence
of LVI). RFS was defined as the time from enrol-
ment to any disease recurrence (local, regional,
distant relapse or a contralateral breast cancer). OS
was defined as the time from enrolment to death.
We wished to learn whether there were significant
initial differences between the risks of relapse or
death among the patients as a function of the
radiomorphological appearance of the tumors.
Hence, the 10-year risks of relapse and mortality
were calculated on the basis of the conventional
prognostic factors (the age, the ER status, grade, size
and nodal status of the tumor) using the software
Adjuvant! [13]. This system provides predicted out-
comes based on the patient and tumor character-
istics. Calculations were made both with and without
the inclusion of the HER2 status. Estimated risks of
relapse and mortality were compared between the
cases with and those without casting calcifications.
Statistical analyses
For the categorical parameters, x2 or Fisher tests
were applied; for the analysis of continuous data, the
Mann-Whitney U-test was used. RFS and OS times
were calculated by means of the Kaplan-Meier
method. Comparisons relating to the presence of
casting calcifications were made with the log-rank
test. To estimate the effect of casting-type calcifica-
tions and the conventional prognostic factors on
long-term disease-outcome, the Cox proportional
hazards model was used. A stepwise selection
method was performed using the likelihood-ratio
statistics based on the maximum partial likelihood
estimates.
Results
The mean patient age was 51.7 (3370) years; 49%
had ER/PR-negative and 20% HER2-/
tumors; the median number of positive lymph nodes
was 6, and 1/3 of the patients had ]10 involved
lymph nodes. Sixty per cent of the tumors were pT2,
and 18% were pT1. Most of the breast tumors were
grade 3 invasive ductal cancers, and 2/3 exhibited
LVI. Among the 55 high-risk breast cancers, ten
displayed the characteristics of casting-type calcifica-
tions. Patient- and tumor-related data according to
the mammographic tumor features are presented in
Table I. Significantly more tumors associated with
casting calcifications were of grade 3 (p0.036),
HER2-positive (p0.012), ER-negative (p0.015)
or PR-negative (p0.003) than in the other group.
No other characteristics of the tumors were related
to the mammographic appearance (Table I).
In order to determine whether there was an ab ovo
difference in the prognosis of the study patients,
depending on the presence or absence of casting-
type calcifications, we performed an analysis based
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on the conventional prognostic factors. The risks of
relapse and death calculated by means of the soft-
ware Adjuvant! are shown in Table II. There was a
trend toward a higher mortality risk in the group
with casting-type calcifications as compared to the
group without them, which became statistically
significant when the HER2 status was included
(Table II).
After a median follow-up time of 29.1 months,
seven (70%) of the ten patients with casting calcifica-
tions had relapsed, and five (50%) had died. Among
these patients, five had distant metastases, one had a
local relapse, and one developed a second primary
breast cancer. The latter two patients underwent
surgery and adjuvant postoperative treatment, and
were alive without evidence of disease at the end of the
follow-up period. Eleven (24.4%) of those patients
who had no casting-type calcifications on the mam-
mogram relapsed, and seven (15.6%) died. Thus,
42% of all death events occurred in the group of
patients having had tumors exhibiting casting calcifi-
cations. RFS and OS were 26.6 and 29.6 months in
the group with casting-type calcifications, and 54.4
and 58.8 months (median), respectively, in the
other group (p0.022 and 0.028, respectively; log-
rank test). In order to estimate long-term prognosis
depending on the presence of casting-type calcifica-
tions, the tumor grade, the LVI, the expressions of
ER/PR and HER2, the tumor size and the nodal
status were studied in a Cox proportional hazards
model. Figure 1 shows cumulative relapse-free survi-
val and overall survival associated with the presence or
absence of casting calcifications on the mammogram.
In the presence of casting-type calcifications, the risks
of relapse and death were increased, with HR3.048
(95% CI: 1.1168.323, p0.030) and HR3.504
(95% CI: 1.07411.427, p0.038). No other pa-
tient- or tumor-related factor exerted a significant
effect on the risk of relapse.
Discussion
This retrospective analysis was performed to assess
the value of casting-type calcifications as a mammo-
graphic indicator of a poor prognosis in high-risk
breast cancer patients. In agreement with earlier
studies [37,11], we found the presence of casting-
type calcifications to be the most powerful indepen-
dent prognostic factor in a group of high-risk
operable breast cancer cases. Our results contribute
to and support the earlier finding that breast tumors
associated with casting-type calcifications on the
mammogram comprise a disease entity which is
clearly different from cancers with other mammo-
graphic tumor features.
The previous studies on the prognostic role of
casting-type calcifications were performed on
screen-detected small cancers [37,11]. Our study
group consisted of more advanced, but operable
cases with large and usually node-positive tumors.
We found more than 3-times higher risks of relapse
and death in the group of tumors associated with
casting-type calcifications as compared with the
group without them. Tabár et al. reported that the
risk of death was 32-times higher in screening-
detected invasive breast cancers smaller than
Table I. Patient- and tumor-related characteristics of 55 high-risk breast cancer cases displaying the presence or absence of casting-type


















Absent (n45) 51.591.2 35.893.1 7.790.8 23 (52.3%) 32 (71%) 24 (53%) 23 (51%) 8 (18%)
Present (n10) 51.993.8 34.297.4 6.991.6 9 (90%) 6 (60%) 1 (10%) 0 (0%) 6 (60%)
p NS NS NS 0.036 NS 0.015 0.003 0.012
LVI, lymphovascular invasion.
Table II. Risks of relapse and death based on conventional prognostic factors (age, grade, ER status, tumor size, nodal status with or
without HER2 status) among the tumor groups with or without casting-type calcifications, as indicated by the software Adjuvant!
Without inclusion of the HER2 status With inclusion of the HER2 status
Casting-type
calcifications Risk of relapse (%) Risk of death (%) Risk of relapse (%) Risk of death (%)
Absent (n45) 71.692.1 56.492.4 71.792.3 56.292.6
Present (n10) 74.894.6 65.995.5 78.795.1 70.796.2
p (Mann-Whitney U-test) 0.395 0.068 0.180 0.033
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10 mm and associated with casting-type calcifica-
tions as compared with those without such calcifica-
tions. The difference in the risk of fatality was
smaller between the cases with and those without
casting-type calcifications when the tumors mea-
sured 1015 mm [5]. We were interested in whether
the worse prognosis associated with casting-type
calcifications would still exist in a set of high-risk,
mostly clinically detected breast cancers, and it
emerged that their presence was paralleled by a
significantly poorer prognosis.
We analyzed whether the conventional prognostic
factors differed between the group of breast tumors
associated with casting-type calcifications and the
group which did not display this mammographic
feature. The tumor size and the nodal status reflect-
ing primarily the stage of the disease did not reveal
any difference between the two groups. The grade 3
phenotype was significantly more common among
the tumors associated with casting-type calcifica-
tions, which is in accordance with the data of other
authors [11,14].
Zunzunegui et al. studied a group of 12 breast
cancer patients with invasive tumors who exhibited
casting-type calcifications [7]. These tumors were
smaller than the ones in our study, and all contained
an extensive intraductal component. Half of them
were ER/PR-negative, while 60% were HER2-posi-
tive. Our data are in consistence with those results,
since all the tumors associated with casting-type
calcifications in our study contained extensive high
grade DCIS components. In fact, we found an even
higher proportion of hormone receptor-negative
cancers among those with casting-type calcifications.
Moreover, HER2 positivity was typical in the cancer
cases with casting-type calcifications. Our findings
also accord with those of Millis et al., who demon-
strated that the histological type of the DCIS
component in invasive tumors was highly correlated
with the grade of the infiltrative part [15], and
predicted survival in 215 infiltrating ductal carcino-
mas after a median follow-up time of 11.2 years [16].
In the study of MacMillan et al., residual micro-
scopic disease after breast conservation surgery was
associated with the mammographic appearance of
casting calcifications and predicted local recurrence
[17]. Casting-type calcifications were the only in-
dependent mammographic feature that predicted
residual cancer cells in the tumor bed and the
consequent risk of local relapse [18]. Among our
seven relapsed patients with cancers associated with
casting-type calcifications, one had a local relapse on
the chest wall.
With a view of analyzing whether the use of
conventional prognostic factors could have predicted
a significant difference between the groups of tumors
with or without casting-type calcifications, we com-
pared the risks of relapse and mortality as predicted
by the software Adjuvant! [13]. Although there was a
non-significant trend toward a greater mortality risk
in the cases exhibiting casting-type calcifications,
there was no difference in the risk of relapse. The
difference in predicted mortality risk between the two
groups became statistically significant when the
HER2 status was included. This latter result does
not contradict, but rather strengthens the hypothesis
that a positive HER2 status and casting-type calcifi-
cations are common features of the same tumor type
with an extremely poor prognosis.
Tabár et al. proposed that invasive breast cancers
associated with casting-type calcifications and grade
3 DCIS comprise a different tumor type in a more
advanced stage than indicated by the conventional
prognostic factors, compared with their counterparts
without this mammographic feature [35]. Neoduct-
genesis in the high-grade DCIS components, as a
special process promoting vascular invasion, and
consequently excessive lymphatic and hematogenous
spread is suggested as a key underlying mechanism
for the worse outcome in these tumors [5]. In
accordance with the findings of Tabar et al., despite
the outstanding difference in outcome, we did not
Figure 1. The effect of the mammographic feature of casting-type
calcifications on recurrence-free (a) and overall survival (b).
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observe any difference between the tumors with or
without casting-type calcifications, as concerns con-
ventional prognostic factors (tumor size, number of
positive lymph nodes, LVI) [3,5]. Our study clearly
demonstrated that tumors with casting calcifications
on the mammogram are typically of ductal type, of
grade 3, ER and PR negative and HER2 positive.
Based on these results, we believe that tumors
associated with casting-type calcifications display
different biological behavior with higher rates of
proliferation and progression than other breast
cancers. It is also probable that tumors with cast-
ing-type calcifications are more resistant to che-
motherapy than tumors without them. This is
indicated by the poor survival of the patients with
invasive cancers measuring 114 mm associated with
casting-type calcifications, irrespective of the ther-
apeutic regimen applied [5]. Our data points to
relative therapy resistance. Our study group con-
sisted of high-risk, uniformly treated breast cancer
patients. Those patients with casting-type calcifica-
tions relapsed and died soon after treatment, despite
the administration of adjuvant dose-dense sequential
paclitaxel-containing chemotherapy. There is an
urgent need for the development of effective treat-
ment methods for this special type of cancer, as none
currently exists [5]. Primary systemic treatment
could be an appropriate setting in which to test the
antitumor potential of new pharmaceuticals, includ-
ing different cytostatics and molecularly targeted
therapies. The two most plausible of the latter group
of agents are possibly trastuzumab and bevacizumab.
Our results demonstrate that the presence of casting-
type calcifications is significantly associated with the
overexpression of HER2. Five randomized studies
recently provided overwhelming evidence that the
addition of trastuzumab to the adjuvant chemother-
apy may halve the risk of early relapse [1922]. The
vascular invasion could be prevented and the patho-
logically leaky vasculature could be normalized by
use of the anti-VEGF bevacizumab [23]. Since most
of the tumors associated with casting-type calcifica-
tions were ER/PR-negative, there is little likelihood
of benefit from hormonal therapy in this group of
patients.
We believe that the detection of casting-type
calcifications at mammography should be a warning
sign of aggressive tumor behavior, irrespective of the
stage of the tumor. Although the number of patients
in our analysis was rather modest, the striking
difference in outcome appears to deserve attention.
Our observations warrant further analyses, and
stress the need for the testing of new treatment
options for the high-risk group of breast cancers
associated with casting-type calcifications.
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